Author

Rotila Hyka

Albert Einstein College of Medicine

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:cancer & tumor microenvironment· 2 Approach:experimental assay· 2 Organism:mouse· 2 Assay:bulk RNA-seq· 1 Research Focus:drug response / drug discovery· 1 Organism:human· 1 Assay:proteomics· 1

Frequent Co-Authors

Ellen AngelesiD· 2 shared Kira GritsmaniD· 2 shared Linde A. MilesiD· 2 shared Seiya KitamuraiD· 2 shared Shira G. Glushakow-SmithiD· 2 shared Aaliyah BattleiD· 1 shared Aditi ShastriiD· 1 shared Alexandra SchureriD· 1 shared

Activity by Year

2025-2026 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 39 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

Ellen AngelesORCID

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Exploiting an Epigenetic Resistance Mechanism to PI3 Kinase Inhibition in Leukemic Stem Cells

Shira G. Glushakow-Smith, Imit Kaur, Simone Sidoli, Shayda Hemmati, Ellen Angeles, Taneisha Sinclair, Samarpana Chakraborty, Aaliyah Battle, Kristina Ames, Swathi-Rao Narayanagari, Rotila Hyka, Mark Soto, Melissa Tracy, Jayaram Vankudoth, Seiya Kitamura, , Kira Gritsman

This study identifies a resistance mechanism in AML leukemic stem cells to PI3K inhibition and shows that combining PI3K and EZH1/2 inhibitors overcomes resistance.

Leukemia · Sep 28, 2026Peer-reviewedCancer Biology

TTLL4 glutamyltransferase is a therapeutic target for NPM1-mutated acute myeloid leukemia

Alexandra Schurer, Humaira Ilyas, Maxim I. Maron, Subray S. Hegde, Melissa R. Leyden, Irene Mariam Roy, Rotila Hyka, Lucas Dada, Jeffrey Shabanowitz, Donald F. Hunt, Ellen Angeles, Victor Morell, Benjamin M. Lorton, Shira G. Glushakow-Smith, Daniel K. Borger, , David Shechter

This study identifies TTLL4 as a therapeutic target in NPM1-mutated AML by showing its role in stabilizing NPM1c and promoting differentiation block, with a small molecule inhibitor demonstrating efficacy.

bioRxiv · Apr 7, 2025 · PreprintCancer Biology